Isomorphic Labs, the Alphabet-owned AI drug discovery company led by Demis Hassabis, is in early talks for a new funding round that could value the business at no less than $40 billion and potentially as high as $50 billion. The development comes only months after the company raised $2.1 billion in a Series B round in May this year. The report also noted that the use of artificial intelligence in biopharma remains at an early stage, with more work still needed before efforts can translate into clinical trials and commercial products. The current fundraising discussions have not progressed to final terms, and no investor details have been disclosed. At this stage, the company’s valuation range, the timing of the round, and the identity of participating backers remain unconfirmed beyond the early negotiations described in the report.
According to ChainCatcher, Isomorphic Labs, the Alphabet-owned AI drug discovery company led by Demis Hassabis, is in early talks for a new funding round at a valuation of at least $40 billion, with the figure possibly reaching $50 billion.
The company completed a $2.1 billion Series B round in May this year.
The report added that AI applications in biopharma are still at an early stage, and that more work is needed before they can move into clinical trials and commercial products.
The fundraising talks remain preliminary. Specific terms and investor information have not been disclosed.
This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan. Disclaimer:
The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.
Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.
